盐酸羟甲唑啉(Oxymetazoline Hydrochloride)-药物靶点：α1A-AR_在研适应症：眼睑下垂，红斑，酒渣鼻_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol

+ [38]

靶点

α1A-AR(肾上腺素能受体α-1a)

作用机制

α1A-AR激动剂(肾上腺素能受体α-1a激动剂)

治疗领域

消化系统疾病、眼部疾病、心血管疾病+ [3]

在研适应症

眼睑下垂、红斑、酒渣鼻+ [4]

非在研适应症

脊髓损伤

原研机构-

在研机构

Allergan, Inc.

RDD Pharma Ltd.

Santen Pharmaceutical Co., Ltd.

+ [6]

非在研机构

Allergan Plc /Icahn/

最高研发阶段批准上市

首次获批日期(全球)

加拿大 (1964-12)

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)

登录后查看首次获批时间轴

结构

分子式C16H25ClN2O

InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N

CAS号2315-02-8

关联

75

项与盐酸羟甲唑啉相关的临床试验

NCT05945615 / Not yet recruiting临床3期IIT

Evaluation of Ophthalmic Oxymetazoline as an Adjunct Treatment for Acquired Blepharoptosis Due to Periocular Synkinesis.

After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.

开始日期2023-11-01

申办/合作机构

Hershey Medical Center

IRCT20230514058190N1 / Suspended临床2/3期

Investigating the effect of Oxymetazoline nasal spray on septorhinoplasty surgery bleeding

开始日期2023-07-01

申办/合作机构

Islamic University of Technology

ACTRN12622001146785 / Suspended临床3期

The efficacy of tetracaine and oxymetazoline as a topical nasal anaesthetic and decongestant for people having nasal endoscopy

开始日期2023-05-18

申办/合作机构

Auckland University

100 项与盐酸羟甲唑啉相关的临床结果

登录后查看更多信息

100 项与盐酸羟甲唑啉相关的专利（医药）

登录后查看更多信息

1,058

项与盐酸羟甲唑啉相关的文献（医药）

2023-11-09·Rhinology

Topical anaesthesia and decongestion in rhinology.

Article

作者: S J M Hale ; R Kim ; R G Douglas

Topical anaesthesia and decongestion of the sinonasal mucosa are used commonly in rhinology practice to facilitate nasal endoscopy, as well as debridement and biopsies. Topical agents used for sinonasal anaesthesia include lignocaine, tetracaine and cocaine. Unlike lignocaine and tetracaine, cocaine also has a decongestant effect. Phenylephrine, oxymetazoline, xylometazoline or adrenaline are usually added to lignocaine and tetracaine to provide decongestion. Several studies have been performed seeking to identify the optimal nasal preparation for nasal endoscopy in the clinic setting. However, there remains no clear consensus in the literature resulting in ongoing wide variation between anaesthetic-decongestant preparations used in clinical practice. Indeed, some authors have argued that no anaesthetic is required at all for flexible nasendoscopy despite the apparent consensus that nasal instrumentation is generally uncomfortable, inferred by the persistence of ongoing research in this area. This review provides a practical summary of local anaesthetic and decongestant pharmacology as it relates to rhinologic practice and summarises the literature to date, with the goal of identifying current gaps in the literature and guiding future research efforts.

2023-10-30·Optometry and vision science : official publication of the American Academy of Optometry

Clinical Report: Clinician Feedback on the Magnetic Levator Prosthesis.

Article

作者: Kevin E Houston ; Melanie Nadeau ; Eleftherios I Paschalis

SIGNIFICANCE:

Stakeholder engagement has been identified by national health organizations as a crucial step to successful translation of new healthcare treatments. In this clinical report, clinician-stakeholder feedback is presented for the Magnetic Levator Prosthesis (MLP), a promising non-invasive spectacle device which restores eyelid motility with magnetic force.

PURPOSE:

To evaluate MLP clinical need and translational barriers.

METHODS:

Ten vision rehabilitation optometrists who attended an educational presentation on the MLP and participated in a hands-on workshop in the fitting of a patient were invited to complete an anonymous online survey. Ten multiple-choice items gathered data on estimated patient need, current approaches, main barriers for MLP, temporary versus chronic use, cost barriers, and need for insurance coverage. Open fields allowed for additional comments.

RESULTS:

Nine of 10 specialists completed the survey. Of those, 7 answered that they could potentially see at least 1-5 patients for ptosis management within a year. The most common ptosis management options reported were the ptosis crutch, taping the eyelid open, and Oxymetazoline drops, all with 6 responses each. Seven clinicians indicated that cost was a main concern. If cost-to-patient was not a barrier, all indicated they would be at least somewhat likely to try the MLP for: 1) temporary management of ptosis, 2) as a pre-surgical trial, and 3) for long term management of ptosis, with more selecting extremely likely and very likely than somewhat likely. Main comments were expressing enthusiasm for the technology and that it would be more appealing for patients if covered by insurance.

CONCLUSIONS:

This clinical report suggests the main barriers to clinical success of the MLP may be cost and insurance coverage, appearance of the device, and self-application. Possible solutions are cost-benefit analysis research, engineering efforts to reduce spectacle magnet size and improve the ease of eyelid magnet application.

2023-10-12·Dermatology and therapy

Emerging Medical Therapies in Rosacea: A Narrative Review.

Review

作者: James Choe ; John S Barbieri

Rosacea is a chronic inflammatory disease with a multifactorial pathogenesis. The wide spectrum of clinical phenotypes, including erythema, telangiectasia, inflammatory papules and pustules, and phyma, demand an individualized approach to treatment. This narrative review offers an updated reference for rosacea management by covering the latest developments in both topical and systemic treatments, including data from newly approved therapies, updates to current treatment modalities and ongoing clinical trials. Although use of benzoyl peroxide as a treatment for rosacea has typically been limited due to irritation, the improved tolerability due to microencapsulation of benzoyl peroxide 5% cream provides a new therapeutic option for patients with rosacea. Minocycline foam and topical ivermectin cream add to our armamentarium of treatment options, particularly for inflammatory papules and pustules. Sarecycline has a narrower spectrum of antibacterial activity, which might reduce the development of antibiotic resistance and disruption of the microbiome compared to other oral antibiotics. Brimonidine gel and oxymetazoline cream provide topical options for redness and flushing. There is emerging evidence about the role of hydroxychloroquine and intradermal botulinum toxin A, which may improve rosacea through their effects on mast cells. The clinical trials pipeline includes agents with a variety of mechanisms, including mast cell stabilization, antimicrobial, anti-inflammatory, and vasoconstrictive effects. However, the clinical pipeline for rosacea appears limited, and there remain important unmet needs for patients with more recalcitrant rosacea or phymatous disease. In addition, there is a need for comparative effectiveness studies to identify the highest value treatment approaches for patients with rosacea.

49

项与盐酸羟甲唑啉相关的新闻（医药）

2023-10-26

·蒲公英Ouryao

违法购买麻醉药品对照品、药企被处罚！

来源：辽宁药监局编辑：wangxinglai2004 2023年10月26日，辽宁药监局发布了1则行政处罚结果公示，丹东药业集团有限公司因未按规定购买麻醉药品对照品被处罚并警告。通知原文案件名称：丹东药业集团有限公司未按规定购买麻醉药品对照品案被处罚企业名称：丹东药业集团有限公司生产地址和生产范围（正本）：辽宁省丹东高新技术产业开发区A-027号：中药饮片(含直接口服饮片)，片剂，硬胶囊剂，散剂，糖浆剂，原料药，颗粒剂，合剂，煎膏剂，滴鼻剂，丸剂***生产地址和生产范围（副本）：辽宁省丹东高新技术产业开发区A-027号：颗粒剂，合剂，煎膏剂，中药饮片(含直接口服饮片)(净制、切制、炒制、炙制、蒸制)，片剂，硬胶囊剂，散剂，糖浆剂，原料药(盐酸羟甲唑啉)，滴鼻剂，丸剂(蜜丸、水丸、水蜜丸)***主要违法事实当事人未经批准，向未经国务院药品监督管理部门批准的单位购买对照品，具体如下：吗啡对照品2支（规格：100mg/支）磷酸可待因对照品（规格：100mg/支）罂粟壳对照品2支（规格：1g/支）处罚结果：没收吗啡对照品1支（规格：100mg/支）、磷酸可待因对照品（规格：100mg/支）；警告。

2023-10-12

·GlobeNewswire-Health Care

RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries

Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals, Inc. and RVL Pharmacy, LLC (the “RVL Subsidiaries”), have reached an agreement with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”), and other key stakeholders, to effectuate a change of control transaction through prepackaged bankruptcy cases commenced in the United States Bankruptcy Court for the District of Delaware today (the “Reorganization”). The Reorganization provides a structured pathway for the RVL Subsidiaries to significantly reduce their debt, while enabling them to streamline operations, maintain jobs and position themselves under new ownership. As a result of the Reorganization, RVL is expected to commence the wind-down of any remaining operations of the Company and its subsidiaries, other than the RVL Subsidiaries. RVL’s public equity is expected to be cancelled upon completion of its wind-down, anticipated to be during 2024, likely resulting in no recovery to public shareholders. Under the Reorganization, funds managed by Athyrium will exchange their outstanding debt into equity of a newly formed entity that will either (1) directly hold 100% of the equity interests of Revitalid Pharmaceutical, Corp., which is currently an indirect wholly owned subsidiary of the Company, or (2) indirectly hold 100% of the equity interests of RVL Pharmaceuticals, Inc., which is currently a wholly owned subsidiary of Revitalid Pharmaceutical, Corp. and the direct parent of RVL Pharmacy, LLC. In addition, funds managed by Athyrium are committed to providing incremental financing facilities to support the RVL Subsidiaries’ operations during the Reorganization and to support their long-term growth and liquidity. The Reorganization will enhance the RVL Subsidiaries’ ability to invest in UPNEEQ, accelerate their strategic initiatives, and allow for the continued delivery of high-quality, innovative ocular and aesthetic solutions for patients and healthcare partners. The Reorganization contemplates that all of RVL Subsidiaries’ vendors, suppliers, and customers will be unaffected by the Reorganization, and their employees will remain employed by these entities. Brian Markison, Chief Executive Officer and Chairman of the Company’s Board of Directors, commented, “This is a significant step forward in securing RVL’s future, ensuring we continue to meet the demands of our patients while also executing our long-term growth strategy. As we move forward, we remain committed to realizing the full commercial potential of UPNEEQ.” The RVL Subsidiaries are being advised by Ropes & Gray LLP, Richards, Layton & Finger, P.A., and A&L Goodbody LLP as legal counsel, Ernst & Young LLP as financial advisor, and Ducera Partners LLC as investment banker. About the Company RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis. The content above comes from the network. if any infringement, please contact us to modify.

并购上市批准

2023-09-24

·赛柏蓝

FDA认定一感冒成分无效？这些药品或受影响

近日，FDA召开非处方药咨询委员会会议，专门讨论口服去氧肾上腺素作为非处方咳嗽和感冒产品活性成分的有效性。委员会讨论了口服去氧肾上腺素有效性的新数据，最终得出一致结论：当前的科学数据，并不支持口服去氧肾上腺素作为鼻减充血剂的有效性（投票结果16：0）。虽然FDA没有明确说明剂量，但大量文献指出，口服去氧肾上腺素（40毫克）无效【1】。这意味着Sudafed PE这样的名牌药物(Sudafed PE约占去氧肾上腺素市场的五分之一)，可能并没有广告中宣传的减轻鼻塞的效果。01去氧肾上腺素的「生前身后名」去氧肾上腺素是一种α-1肾上腺素能受体激动剂，通过刺激鼻道血管内壁平滑肌上的受体，缩小鼻道中的血管，从而减少肿胀和充血，通常用于缓解由普通感冒、过敏或鼻窦炎等疾病引起的鼻塞和不适。尽管咨询委员会对口服去氧肾上腺素的有效性提出了否定，但其是否等同于“无效”还需由FDA正式认定。FDA声明中涉及一项关键内容，即咨询委员会的建议仅涉及“口服”去氧肾上腺素（片剂或胶囊），而不针对鼻喷雾剂。FDA还表示，含有去氧肾上腺素的药物，对于散瞳和手术期间使用同样有效，并不受到此次决定的影响。对此，佛罗里达大学药学博士Leslie Hendeles表示，“只有口服途径是无效的，因为99%的母体药物在肠道和肝首过代谢时就失活了”。Hendeles领导了佛罗里达大学2015年提交的公民请愿书，要求从OTC鼻减充血剂产品的OTC monograph中删除口服去氧肾上腺素。通常来说，当一种OTC药物从OTC monograph中删除，可能会对消费者、制造商和监管环境产生重大影响。例如，若去氧肾上腺素最终遭到FDA除名，伪麻黄碱的需求量可能会激增，以填补去氧肾上腺素的空缺。而后续的监管部门药物管控、患者药物获取等都会受到影响。笔者在药智数据库查询发现，国内上市药品中，含有去氧肾上腺素的口服非处方药包含柳酚咖敏片等品种，其去氧肾上腺素的剂量大多在2.5mg-5mg之间。除了化学减充血剂药物之外，桉树油、薄荷醇、生姜、大蒜、蜂蜜等自然疗法也具有缓解鼻塞的潜力。不知道这对于拥有悠久草本入药历史的中国来说，是否意味着机遇？02哪些品种将受影响？FDA官方网站上发布的声明称，有些产品只含有去氧肾上腺素，而某些产品则含有去氧肾上腺素和另一种活性成分（例如对乙酰氨基酚或布洛芬），可针对鼻塞之外的其它症状，例如头痛或肌肉酸痛等，这些产品中的去氧肾上腺素的存在，并不会影响其他活性成分治疗这些症状。FDA表示，含有去氧肾上腺素成分的产品大约有250种，其在2022年的销售额约为18亿美元。包括Tylenol、NyQuil、Mucinex、Theraflu和Benadryl等知名感冒和流感产品。如果FDA遵循咨询小组的建议，强生、拜耳和其他制药商可能会被要求从商店货架上撤下含有去氧肾上腺素的口服药物。这可能会迫使消费者转而使用非处方药，或者使用含有去氧肾上腺素的鼻喷雾剂和滴剂。美国消费者保健产品协会(CHPA，The Consumer Healthcare Products Association)于9月12日发表声明，对FDA咨询委员会的调查结果表示失望，并敦促FDA将去氧肾上腺素继续留在市场上。CHPA表示，撤销去氧肾上腺素的非处方药资格将对医药市场造成明显的破坏性。除名去氧肾上腺素的决定将增加消费者负担，原本可以轻松从药店购买到的OTC可能会无迹可寻。患者需要寻求替代疗法，或者向医生寻求处方，这将导致就诊次数和医疗费用增加。CHPA还认为，除名去氧肾上腺素，无论对医药成本、患者依从性、供应链，都将造成意义深远的影响。FDA数据显示，去年美国零售店销售了2.42亿瓶含有去氧肾上腺素的药物，比2021年增长了30%。这些产品去年的销售额为18亿美元。03剥夺非处方药资格后，巨大空缺谁来填补？如果去氧肾上腺素最终被FDA剥夺了非处方药资格，其留下的巨大空缺将由谁来填补？伪麻黄碱（Pseudo-ephedrine）算得上一号。伪麻黄素是一种去除鼻塞和鼻窦充血的药物，有效收缩鼻腔和鼻窦中的血管，从而减轻鼻塞和流感症状，通常用于治疗感冒、过敏性鼻炎和鼻窦炎等呼吸道疾病的症状。实际上，伪麻黄碱因为可以当作合成甲基苯丙胺的原料，甲基苯丙胺就是俗称的冰毒。受甲基苯丙胺影响，许多国家对伪麻黄素的销售和购买都有限制，并要求购买者提供身份信息，以确保合法使用。含有伪麻黄碱的产品仍然可以作为非处方药购买，但获取伪麻黄素药物不可能像去氧肾上腺素那样轻而易举。相比于去氧肾上腺素2022年2.42亿瓶和18亿美元的销售额，同期伪麻黄素的销量估计为5100万件，销售额为5.42亿美元。除了去氧肾上腺素和伪麻黄素之外，获批的nasal decongestant还包括：Levomethamphetamine（左旋甲基苯丙胺，甲基苯丙胺的L-对映体，亦称左旋甲基安非他命）:一种拟交感神经血管收缩剂，用于美国的一些非处方(OTC)鼻减充血剂。不同于右旋甲基苯丙胺，它在低剂量没有造成欣快或成瘾的特性。Oxymetazoline（羟甲唑啉）：一种α-1A肾上腺素受体激动剂，可用于治疗鼻充血、眼睛过敏反应以及与红斑痤疮相关的面部红斑。羟甲唑啉可作为鼻减充血剂用于非处方鼻用产品中。羟甲唑啉具有良好的外周血管收缩作用，直接激动血管α-1受体，引起鼻腔黏膜血管收缩，从而减轻炎症所致的充血和水肿。它起效迅速，在几分钟内即可发生作用，可维持数小时，能有效地解除鼻充血。Ephedrine（麻黄碱）：一种α和β肾上腺素能激动剂，用于治疗麻醉下低血压、过敏性疾病、支气管哮喘和鼻塞。Propylhexedrine（丙己定）：一种α-肾上腺素能激动剂，常用于鼻减充血吸入剂。它用于暂时缓解感冒、过敏性鼻炎或过敏引起的鼻塞。Xylometazoline（丁苄唑啉，亦称赛洛唑啉）：一种直接作用的α-肾上腺素能激动剂，用于对过敏或感冒引起的鼻充血和轻微炎症的对症治疗。不建议使用超过七天。同样，不建议三个月以下的婴儿使用，有的说法甚至建议不要在6岁以下儿童使用。虽然当前的科学数据并不支持口服去氧肾上腺素作为鼻减充血剂的有效性，但相关药品市场受到的直接影响还要等待FDA下一步动作。END作者 | 骎丹翼来源 | 药智网赛柏蓝药械交流46群扫描下方二维码进入赛柏蓝药械交流群医药代表转型之患者招募扫描下方二维码进入赛柏蓝患者招募群

100 项与盐酸羟甲唑啉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01022	盐酸羟甲唑啉	S01GA04 R01AB07 R01AA05	DB00935

研发状态

适应症	最高研发状态	国家/地区	公司
鼻塞	批准上市	中国更多	常州亚邦制药有限公司更多
眼睑下垂	批准上市	美国更多	RVL Pharmaceuticals, Inc. 更多
红斑	批准上市	美国更多	EPI Health LLC 更多
老花眼	临床2期	美国更多	Allergan, Inc. 更多
大便失禁	临床1期	美国更多	RDD Pharma Ltd. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04831047 (CTgov)	临床4期	红斑 \| 眼睑下垂 \| 结膜炎 ... 更多	114	Oxymetazoline hydrochloride 0.1% ophthalmic solution (Upneeq Group)	鹹餘憲廠鹹選醖構衊鏇(糧選積鏇築蓋網膚夢範) = 願鏇憲範廠鹹壓顧膚網襯願簾鬱鏇鬱醖膚醖獵 (願積壓觸鏇鬱醖糧簾夢, 構齋獵齋鹹膚糧鏇衊窪 ~ 構鏇鑰獵繭範夢簾齋膚) 更多	-	2023-04-24
				Placebo (Control Group)	鹹餘憲廠鹹選醖構衊鏇(糧選積鏇築蓋網膚夢範) = 糧製衊遞糧餘顧膚簾夢襯願簾鬱鏇鬱醖膚醖獵 (願積壓觸鏇鬱醖糧簾夢, 餘艱觸鑰網觸夢衊鑰壓 ~ 艱鏇餘艱鏇鹽衊顧齋鬱) 更多
NCT04153188 (CTgov)	临床4期	酒渣鼻	34	The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream)	膚齋積蓋積範願夢遞餘(範憲選積膚醖構築窪鹽) = 鹹顧積壓獵遞膚築鹹醖襯蓋艱簾窪艱鑰網餘餘 (衊窪廠蓋製鏇繭觸廠壓, 鏇願鬱衊餘觸齋憲築顧 ~ 製壓鏇醖糧艱網憲齋壓) 更多	-	2022-03-18
				Oxymetazoline HCL 1% Cream (Oxymetazoline HCL 1% Cream)	膚齋積蓋積範願夢遞餘(範憲選積膚醖構築窪鹽) = 壓繭膚壓遞淵遞顧醖憲襯蓋艱簾窪艱鑰網餘餘 (衊窪廠蓋製鏇繭觸廠壓, 鬱遞遞範構願窪淵顧鏇 ~ 鏇襯願醖簾廠衊顧糧窪) 更多
NCT01848041 (CTgov)	临床1/2期	眼睑下垂	46	RVL-1201 (RVL-1201 Once Daily)	壓獵願醖壓顧膚廠蓋製(廠網衊鏇襯範獵鬱夢淵) = 膚齋觸簾襯廠醖製製構範遞鏇蓋築築艱鬱積餘 (簾夢憲鏇願願繭願鹹鏇, 夢蓋顧壓網積壓鹹願廠 ~ 襯夢構鑰築鬱築築淵鑰) 更多	-	2021-07-22
				RVL-1201 (RVL-1201 Twice Daily)	壓獵願醖壓顧膚廠蓋製(廠網衊鏇襯範獵鬱夢淵) = 鑰顧窪鏇繭構選蓋網積範遞鏇蓋築築艱鬱積餘 (簾夢憲鏇願願繭願鹹鏇, 鬱衊製齋艱繭鑰鹽獵齋 ~ 餘夢蓋襯壓艱襯積廠夢) 更多
NCT03954444 (CTgov)	临床3期	酒渣鼻	1,105	Oxymetazoline Hydrochloride (Oxymetazoline Hydrochloride Cream, 1%)	遞鑰醖築簾蓋艱遞鬱壓(鹽鹽鑰艱網衊淵鹽壓積): Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0)	-	2021-06-23
				Rhofade Cream, 1% (RHOFADE Cream, 1%)
NCT03228914 (CTgov)	临床4期	鼻息肉 \| 出血	20	Oxymetazoline (Oxymetazoline)	簾糧淵鹹繭積觸積蓋獵(鹽遞齋選膚壓鏇築膚範) = 襯遞築衊淵憲糧窪繭範窪鑰餘衊網夢壓願艱積 (蓋襯壓觸觸襯遞鑰遞構, 襯遞簾觸醖觸構憲範構 ~ 窪鏇襯壓築窪製壓醖衊) 更多	-	2021-01-13
				Epinephrine (Epinephrine)	簾糧淵鹹繭積觸積蓋獵(鹽遞齋選膚壓鏇築膚範) = 窪窪鏇糧壓蓋淵窪壓範窪鑰餘衊網夢壓願艱積 (蓋襯壓觸觸襯遞鑰遞構, 構築構齋餘廠膚繭觸遞 ~ 壓遞糧築積製網夢構憲) 更多
NCT03352323 (CTgov)	临床3期	酒渣鼻 \| 红斑	50	Oxymetazoline	範餘獵鏇衊積憲蓋觸壓(憲遞衊夢夢鬱願構鏇襯) = 簾窪淵衊簾艱憲廠夢獵鏇醖齋範繭構簾繭膚壓 (構築壓鏇築網糧構鹽顧, 築壓構膚顧憲憲簾醖壓 ~ 壓簾衊糧鏇選壓壓顧鹹) 更多	-	2021-01-05
NCT02780115 (CTgov)	临床2期	老花眼	151	AGN-190584 Vehicle	壓築製觸窪鏇簾積淵鹹(齋廠簾鑰蓋選範餘蓋鑰) = 膚網窪鹹膚膚糧繭選廠鏇範廠窪獵構夢獵製窪 (遞積獵醖膚夢網夢淵醖, 鬱繭觸築淵製選鏇願窪 ~ 網鑰繭廠鹹獵憲獵製遞) 更多	-	2020-12-22
NCT02595528 (CTgov)	临床2期	老花眼	163	AGN-190584 (AGN-190584 Vehicle)	鹽顧醖製顧餘壓鑰廠製(製鹹鹹簾蓋鬱廠襯壓鏇) = 淵願鬱顧窪獵築鑰鏇餘製積蓋築觸獵鬱壓顧觸 (遞願衊夢憲壓獵壓觸選, 餘觸醖構積齋築膚淵鹹 ~ 蓋顧構壓鹽醖築範廠構) 更多	-	2020-12-22
				AGN-190584 (AGN-190584 Lower Dose)	鹽顧醖製顧餘壓鑰廠製(製鹹鹹簾蓋鬱廠襯壓鏇) = 艱齋積築蓋餘衊構鑰顧製積蓋築觸獵鬱壓顧觸 (遞願衊夢憲壓獵壓觸選, 蓋鏇艱遞選壓憲窪繭繭 ~ 襯積糧鏇選選齋觸繭積) 更多
NCT03565887 \| NCT02436759 (Pubmed) 人工标引	临床3期	眼睑下垂	304	Oxymetazoline Hydrochloride	鹽醖顧製構築積鏇構糧(顧鑰積醖餘遞廠窪繭遞) = 積鹽願積蓋簾壓獵膚艱艱鹽顧鏇鑰範鏇淵築壓 (鹹鹹鹽膚網糧衊簾顧範, 6.4) 更多	积极	2020-11-01
				vehicle	鹽醖顧製構築積鏇構糧(顧鑰積醖餘遞廠窪繭遞) = 簾鑰艱壓襯鑰願構廠餘艱鹽顧鏇鑰範鏇淵築壓 (鹹鹹鹽膚網糧衊簾顧範, 4.1) 更多
NCT02436759 (CTgov)	临床3期	眼睑下垂	140	RVL-1201	醖鏇觸網醖鹽衊廠鹽網(齋構夢鹽構築鏇鹽淵簾) = 網選蓋襯淵鹽鑰選糧憲襯窪簾憲顧蓋簾範蓋淵 (夢衊膚繭遞網遞構顧構, 廠築壓鏇窪鏇製糧糧積 ~ 遞範壓願構蓋憲襯憲壓) 更多	-	2020-10-20